Premium
Hyperuricaemia and gout in N ew Z ealand rural and urban M āori and non‐ M āori communities
Author(s) -
Stamp L. K.,
Wells J. E.,
Pitama S.,
Faatoese A.,
Doughty R. N.,
Whalley G.,
Richards A. M.,
Cameron V. A.
Publication year - 2013
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12062
Subject(s) - gout , medicine , anthropometry , uric acid , population , demography , gerontology , physical therapy , environmental health , sociology
Background There are few current data on the prevalence of hyperuricaemia and gout in N ew Z ealand, particularly among the indigenous M āori population. Aims To determine the prevalence of gout and hyperuricaemia in rural and urban M āori and non‐Māori community samples and describe the treatment and comorbidities of participants with gout. Methods Participants aged 20–64 years were recruited by random selection from the electoral roll. M āori samples were selected from among those identified as being of M āori descent on the roll and who self‐identified as being of M āori ethnicity at interview. Personal medical history, blood pressure, anthropometrics, fasting lipids, glucose, HbA1c and urate were recorded. Results There were 751 participants. Mean serum urate ( SU ) was 0.30 mmol/L (0.06–0.69 mmol/L). M āori had a significantly higher prevalence of hyperuricaemia ( SU > 0.40 mmol/L) compared with non‐ M āori (17.0% vs 7.5%, P = 0.0003). A total of 57 participants had a history of gout, with a higher prevalence in M āori compared with non‐ M āori (10.3% vs 2.3%, P < 0.0001). Of the participants, 18/57 (31.6%) with gout were receiving urate‐lowering therapy, but in 38.9%, SU was >0.36 mmol/L. Participants with gout were more likely to have metabolic syndrome, diabetes, cardiac disease or hypertension. Conclusions Gout and hyperuricaemia were more prevalent in M āori, and participants with gout were more likely to have comorbidities. There was not a higher overall adjusted cardiovascular disease risk in M āori participants with gout. Despite the high prevalence of gout, management remains suboptimal.